# Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

> **NCT01546987** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 239 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** GnRH agonist
- **DRUG:** Anti-androgen
- **DRUG:** TAK-700
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT01546987
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2021-11-01
- **Final completion:** 2025-09-04
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546987, "Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01546987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*